Why Glooko’s FDA-cleared EndoTool IV Cloud could reshape hospital glycemic management
Insulin dosing is moving to the cloud. Glooko’s FDA clearance raises bigger questions on hospital workflow, safety, and scale.
Medical Devices & Diagnostics
Pharma & Biotech
Can Assertio give Zydus a faster route into U.S. specialty oncology care?
Zydus gets a U.S. oncology platform, but Rolvedon concentration risk will decide whether the Assertio deal becomes strategic or merely opportunistic.
Medical Devices & Diagnostics
Can Aridol give Arna Pharma and Slate Run a sharper entry into U.S. respiratory diagnostics?
Specialty pharma needs sharper U.S. routes to market. Arna Pharma and Slate Run are testing that model with Aridol and 505(b)(2) products.
Medical Devices & Diagnostics
Why Veracyte’s Medicare win for TrueMRD could reshape bladder cancer recurrence monitoring
MRD testing has payer momentum, but clinical adoption is tougher. Veracyte’s TrueMRD Medicare win puts bladder cancer monitoring in focus.
Medical Devices & Diagnostics
Valar Labs FDA breakthrough nod signals new test for AI-led bladder cancer risk prediction
Bladder cancer risk tools leave gray zones. Valar Labs’ FDA breakthrough nod tests whether AI pathology can narrow them.
Medical Devices & Diagnostics
Why Telix is taking PSMA-PET deeper into minimally invasive prostate cancer treatment
Prostate ablation is getting more precise. Telix wants PSMA-PET to become the imaging layer that helps clinicians decide where to treat.
Pharma & Biotech
Why UroGen Pharma Ltd. sees UGN-103 as more than a follow-on bladder cancer therapy
UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Find out what this means for NMIBC treatment and regulation.
Pharma & Biotech
How Tenaya Therapeutics, Inc. is positioning TN-401 against the limitations of current ARVC care
Could TN-401 change ARVC treatment strategy? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.
Pharma & Biotech
Charles River and MEDIPOST deepen cell therapy testing push across APAC and North America
Cell therapy scale-up is not just a science problem. Charles River and MEDIPOST are targeting the GMP testing bottleneck.
Pharma & Biotech
Catalent’s Elpida Therapeutics deal shows why AAV manufacturing is still a strategic choke point
Ultra-rare gene therapies need more than science. Elpida’s Catalent deal tests whether AAV manufacturing can keep patients within reach.